Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Gains from Investment Securities (2024 - 2025)

BioAge Labs (BIOA) has disclosed Gains from Investment Securities for 2 consecutive years, with $230961.0 as the latest value for Q3 2025.

  • Quarterly Gains from Investment Securities rose 344.99% to $230961.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $3.0 million for FY2025, 44.94% down from the prior year.
  • Gains from Investment Securities hit $230961.0 in Q3 2025 for BioAge Labs, down from $2.9 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $3.1 million in Q1 2025 to a low of -$102000.0 in Q4 2024.